Severe Ulcerative Colitis Flare Admission Order Set
A structured 72-hour decision pathway for hospitalized severe UC: workup, IV steroids, day-3 rescue, and surgical triggers.
Order Set Overview
Acute severe ulcerative colitis (ASUC) is a life-threatening manifestation of inflammatory bowel disease defined by Truelove and Witts criteria as ≥6 bloody stools per day plus at least one systemic feature (heart rate >90 bpm, hemoglobin <10.5 g/dL, ESR >30 mm/hr, fever ≥37.8°C, or albumin <3.0 g/dL). Hospital mortality in the modern era is 1–2% with structured care, but rises to 10–30% if surgery is delayed in steroid-refractory disease. The 30-day colectomy rate is approximately 30%, the cumulative lifetime colectomy rate after one ASUC episode approaches 40%, and roughly 50% of those colectomies occur during the index hospitalization.
This order set codifies a 72-hour decision pathway: rapid stratification and infection exclusion on day 0–1, intravenous corticosteroids initiated within 6 hours of admission, formal day-3 reassessment using Oxford or Travis criteria, and timely escalation to medical rescue therapy (infliximab or cyclosporine) or urgent colectomy if criteria for steroid failure are met. Concurrent attention to thromboprophylaxis, electrolyte derangement, nutritional support, surgical consultation by day 3, and stewardship of antimotility and analgesic medications minimizes complications and shortens length of stay.
1. Admission Criteria and Initial Triage
The decision to admit a patient with a UC flare is anchored to objective severity criteria rather than subjective patient distress alone. The Truelove-Witts criteria, although derived in 1955, remain the most widely validated stratification tool and underpin contemporary ECCO and AGA guideline definitions of acute severe UC.
Truelove-Witts severity classification
| Criterion | Mild | Moderate | Severe |
|---|---|---|---|
| Bloody stools/day | <4 | 4–6 | ≥6 |
| Pulse (bpm) | Normal | Variable | >90 |
| Temperature (°C) | Normal | Variable | ≥37.8 |
| Hemoglobin (g/dL) | Normal | Variable | <10.5 |
| ESR (mm/hr) | ≤30 | Variable | >30 |
| Albumin (g/dL) | Normal | Variable | <3.0 |
Severe UC = ≥6 bloody stools/day PLUS at least one systemic feature (pulse, temperature, hemoglobin, ESR, or albumin). All such patients warrant admission to a center with IBD and colorectal surgery expertise.
Admission triggers (any of the following)
Inpatient admission criteria
- Meets Truelove-Witts severe UC criteria
- Failure of outpatient oral steroid taper (no improvement after 3–5 days of prednisone 40–60 mg PO daily)
- Inability to maintain hydration or nutrition
- Significant orthostatic hypotension or hemodynamic instability
- Severe abdominal pain disproportionate to clinical assessment (consider toxic megacolon)
- Suspicion for toxic megacolon, perforation, or massive hemorrhage
- Pregnancy with active flare regardless of trimester
- Pediatric severe UC (admit to pediatric IBD center)
- Inadequate social support for safe outpatient management
Disposition decisions
Routine severe UC patients can be admitted to a gastroenterology or general medicine ward. ICU-level care is indicated for hemodynamic instability requiring vasopressors, suspected perforation, massive lower GI hemorrhage requiring multi-unit transfusion, severe sepsis, or any patient with toxic megacolon for q4-hour clinical and radiographic monitoring. Early gastroenterology and colorectal surgery consultation should occur within 12 hours of admission for all severe UC patients—surgical familiarity from day 1 prevents delay if escalation becomes necessary.
2. Day-0 Workup and Infection Exclusion
The most consequential errors in the first 24 hours are anchoring on UC flare without excluding infection (especially C. difficile and CMV) and underestimating the magnitude of fluid, electrolyte, and protein losses. The day-0 workup is geared toward simultaneously confirming severity, excluding alternative or superimposed pathology, and obtaining the surgical and pathological data needed to guide day-3 decisions.
Required laboratories
Day-0 laboratory orders (all patients)
- CBC with differential (Hb, WBC, platelets)
- Comprehensive metabolic panel including albumin, total protein, magnesium, phosphate
- CRP and ESR
- PT/INR, PTT
- Type and screen (active type and crossmatch if Hb <9 or active hemorrhage)
- Lactate
- Blood cultures × 2 if febrile or hemodynamically unstable
- Hepatitis B sAg, sAb, cAb (anti-HBc) — required before biologic exposure
- Hepatitis C antibody
- HIV antigen/antibody
- QuantiFERON-TB Gold or T-SPOT.TB — required before biologic rescue
- Pregnancy test (β-hCG) for women of childbearing potential
- Vitamin D 25-OH, ferritin, iron studies, folate, B12 (baseline for outpatient repletion)
Stool studies and CMV evaluation
| Test | Indication | Action if positive |
|---|---|---|
| C. difficile EIA + GDH + PCR (NAAT) | All severe UC admissions | Vancomycin 125 mg PO QID × 14 days; do NOT stop UC therapy |
| Stool culture | All admissions | Treat per organism (Salmonella, Shigella, Campylobacter, Yersinia, E. coli O157) |
| Stool ova and parasites × 3 | Travel history, immunosuppression, eosinophilia | Treat per organism (Entamoeba, Strongyloides) |
| Stool calprotectin | If diagnostic uncertainty | >250 µg/g supports active inflammation; not specific to UC |
| CMV serum PCR / colonic biopsy IHC | Steroid-refractory disease, severe disease, or CMV viremia history | If significant tissue load, ganciclovir 5 mg/kg IV q12h × 14–21 days; continue UC treatment |
Imaging
Imaging orders (severe UC)
- Plain abdominal radiograph (KUB) on admission to assess for colonic dilation, mucosal islands, free air, and small bowel ileus
- Repeat KUB daily during high-risk period (first 72 hours, after rescue, after any clinical change)
- CT abdomen/pelvis with IV contrast if peritoneal signs, suspected perforation, abscess, or atypical presentation
- Avoid colonoscopy with full bowel prep — limited unprepped flexible sigmoidoscopy is preferred (see below)
Flexible sigmoidoscopy
Limited unprepped flexible sigmoidoscopy within 24–48 hours of admission confirms severity, excludes infection (especially CMV), and provides tissue biopsies. Reach should be limited (typically to descending colon, ~30–40 cm) with minimal insufflation to avoid perforation. A Mayo endoscopic subscore of 3 (spontaneous bleeding, ulceration) confirms severe disease and predicts poor steroid response. Biopsies should specifically request CMV immunohistochemistry (IHC) and PCR-based testing, particularly if the patient has prior steroid exposure or refractory disease. Do NOT perform full colonoscopy or push beyond a fragile inflamed sigmoid—the perforation risk is unacceptably high in ASUC.
3. First-Line Therapy: IV Corticosteroids
Intravenous corticosteroids are the established first-line treatment for acute severe UC and should be initiated within 6 hours of admission once infection has been excluded (or empirically, with concurrent infection workup). Approximately 60–70% of patients respond, but 30–40% will fail and require rescue medical therapy or colectomy.
Steroid dosing orders
Day-1 steroid orders
- Methylprednisolone 60 mg IV daily (single daily dose) OR Methylprednisolone 16 mg IV q8h (40–60 mg/day total)
- Alternative: Hydrocortisone 100 mg IV q6h (400 mg/day total)
- Higher doses (e.g., methylprednisolone >60 mg/day) provide no incremental benefit and increase adverse effects
- Pulse-dose steroids (1 g methylprednisolone) NOT recommended in ASUC
- Pediatric: methylprednisolone 1–1.5 mg/kg/day IV (max 60 mg)
- Continue for 3–5 days; transition to oral prednisone 40–60 mg daily once response achieved, with taper of 5 mg/week
Concurrent supportive care
Supportive care orders
- IV fluids: balanced crystalloid (lactated Ringer's or Plasmalyte) 1.5–2× maintenance to replace ongoing losses; titrate to urine output ≥0.5 mL/kg/hr and normalization of lactate
- Daily weights and strict intake/output documentation
- Potassium replacement to maintain K+ ≥4.0 mEq/L; magnesium ≥2.0 mg/dL; phosphate ≥3.0 mg/dL
- Iron infusion (ferric carboxymaltose or iron sucrose) if Hb <10 with iron deficiency (oral iron poorly tolerated and ineffective in active flare)
- Albumin 25% IV 50 mL q12h if albumin <2.5 g/dL with peripheral edema or hypotension (controversial; consider oncotic support during rescue therapy)
- RBC transfusion if Hb <7 g/dL (or <8 with cardiac comorbidity)
- Nutrition: enteral diet (clear liquids advancing as tolerated) preferred; total parenteral nutrition only if intractable vomiting, ileus, or surgical NPO status >5 days
- Stress ulcer prophylaxis (PPI, e.g., pantoprazole 40 mg IV daily) — already on steroids and acutely ill
- Glucose monitoring q6h; sliding scale insulin for steroid-induced hyperglycemia
VTE prophylaxis (mandatory)
VTE risk in active UC
Hospitalized patients with active UC have a 3–6× increased risk of venous thromboembolism compared to other medical admissions, even in the presence of bloody diarrhea. Bleeding from the inflamed colon does NOT contraindicate prophylaxis. Multiple RCTs and observational studies confirm that pharmacologic VTE prophylaxis does not increase clinically significant lower GI bleeding in this population.
VTE prophylaxis orders
- First-line: Enoxaparin 40 mg SC daily (CrCl ≥30) — start within 24 hours of admission
- Renal adjustment (CrCl 15–30): Enoxaparin 30 mg SC daily
- CrCl <15 or weight <50 kg: unfractionated heparin 5000 units SC q8h
- Mechanical prophylaxis (intermittent pneumatic compression) ALONE only if absolute contraindication to anticoagulation (massive hemorrhage requiring transfusion >2 units/24 hr, planned procedure within 12 hours)
- Hold dose 12 hours before any planned endoscopy, biopsy, or surgery
- Continue throughout admission and consider extended prophylaxis post-discharge for high-risk patients
Medications to avoid
Discontinue or avoid
- Antimotility agents (loperamide, diphenoxylate-atropine) — risk of toxic megacolon
- Anticholinergics (hyoscyamine, dicyclomine) — same risk
- NSAIDs — exacerbate mucosal inflammation and bleeding
- Narcotic analgesics in high doses — mask peritoneal signs, promote ileus and toxic megacolon. Use only sparingly and avoid scheduled opioids
- 5-ASA (mesalamine) — discontinue during admission; no incremental benefit during severe flare and may worsen diarrhea in ~5% of patients
- Empiric antibiotics — not routinely indicated unless suspected toxic megacolon, perforation, sepsis, or proven coinfection
4. Day-3 Reassessment and Rescue Triggers
Day 3 is the most important inflection point in the ASUC pathway. Multiple validated criteria identify patients destined to fail steroid therapy with ~85% accuracy, allowing prompt escalation to medical rescue or surgery before catastrophic deterioration.
Oxford criteria (Travis index)
| Day-3 finding | Risk of steroid failure |
|---|---|
| Stool frequency >8/day | ~85% |
| Stool frequency 3–8/day AND CRP >45 mg/L | ~85% |
| Stool frequency 3–8/day AND CRP ≤45 mg/L | Continue steroids; reassess day 5 |
| Stool frequency <3/day, no blood | Likely steroid responder; continue and plan transition |
Patients meeting Oxford criteria for predicted steroid failure should have rescue therapy initiated or surgical decision made by day 5 at the latest. Continued IV steroid administration beyond day 7 in non-responders without escalation is associated with substantially worse outcomes including increased operative mortality.
Other validated severity scores
| Score | Components | Threshold predicting colectomy |
|---|---|---|
| Ho index | Mean stool frequency, colonic dilation, hypoalbuminemia | Score ≥4 predicts colectomy |
| Lindgren score | Stool frequency × 0.14 + CRP × 0.0003 | >8 predicts steroid failure |
| Scottish (Edinburgh) index | Stool frequency, colonic dilation, albumin, mucosal severity | Score ≥4 predicts colectomy |
| Swedish index | Multifactorial (stool frequency, CRP, albumin, fever) | Composite higher than threshold |
Surgical consultation
All ASUC patients should have colorectal surgery consultation by day 3. Early surgical involvement allows the patient and family to develop rapport with the surgical team, understand stoma considerations, and reduces decision delays if rescue therapy fails. Specifically, the colorectal team should perform stoma marking and review the implications of subtotal colectomy with end ileostomy regardless of whether immediate surgery is planned.
Day-3 escalation: do not delay
The most consequential error in ASUC management is continuing IV steroids beyond day 5–7 in a non-responder hoping for late improvement. Each additional day of unmitigated severe disease increases postoperative mortality if surgery becomes necessary. Make a definitive decision—rescue therapy OR surgery—by day 5 in any patient meeting Oxford criteria.
5. Medical Rescue: Infliximab vs Cyclosporine
For steroid-refractory ASUC, two rescue therapies have head-to-head comparable efficacy: infliximab (anti-TNF) and intravenous cyclosporine. The CYSIF trial (2012) and the CONSTRUCT trial (2016) demonstrated similar 3-month colectomy rates and 1-year quality of life outcomes between the two strategies. Selection is therefore individualized based on patient characteristics, contraindications, prior medication exposures, and institutional expertise.
Selection algorithm
| Factor | Favors infliximab | Favors cyclosporine |
|---|---|---|
| Prior anti-TNF exposure | — | ✓ (avoid retreatment if prior IFX failure) |
| Prior thiopurine exposure | ✓ (long-term maintenance with IFX) | — |
| Cholesterol <120 mg/dL or hypomagnesemia | ✓ | Contraindicated (seizure risk) |
| Active infection or untreated TB | Contraindicated | Use cautiously |
| Renal impairment | ✓ | Caution; monitor closely |
| Pregnancy | ✓ (IFX preferred) | Use only if IFX contraindicated |
| Heart failure (NYHA III–IV) | Contraindicated (IFX worsens HF) | ✓ |
| Need for long-term maintenance | ✓ (IFX or other biologic continues) | — (CSA is bridge to thiopurine or biologic) |
Infliximab rescue
Infliximab rescue orders
- Pre-treatment screening: TB (QuantiFERON), HBV (sAg, sAb, cAb), HCV antibody, HIV, CXR — must be complete or accepted high-risk waiver
- Standard induction: Infliximab 5 mg/kg IV at weeks 0, 2, 6
- Accelerated/intensified induction (severe disease, low albumin, large stool burden): Infliximab 10 mg/kg IV at weeks 0, 1, 4 OR Infliximab 5 mg/kg IV at weeks 0, 1, 4
- Pre-medication: acetaminophen 650 mg PO + diphenhydramine 25 mg IV ± hydrocortisone 100 mg IV (already on steroids)
- Infusion duration: 2 hours (extended to 4 hours if previous reaction)
- Monitor vital signs q15min during infusion and 1 hour post
- Continue IV steroids until clinical response, then transition to oral taper
- Initiate maintenance infliximab 5 mg/kg q8 weeks (or per response) post-discharge
- Trough level monitoring at week 14 to optimize dose
Cyclosporine rescue
Cyclosporine rescue orders
- Pre-treatment screening: cholesterol >120 mg/dL, magnesium >1.5 mg/dL, normal renal and hepatic function
- Continuous IV infusion: Cyclosporine 2 mg/kg/day IV continuous infusion
- Lower-dose protocol (acceptable in severe disease): Cyclosporine 4 mg/kg/day IV divided q12h
- Target whole-blood trough: 250–400 ng/mL (HPLC method); check daily for first 5 days, then 2–3×/week
- Continue IV cyclosporine 5–7 days; if response, transition to oral cyclosporine 8 mg/kg/day divided q12h × 3 months
- Initiate thiopurine (azathioprine 2.0–2.5 mg/kg/day or 6-mercaptopurine 1.0–1.5 mg/kg/day) within 1 week of response (check TPMT before starting)
- PJP prophylaxis: TMP-SMX SS daily during cyclosporine + steroid + thiopurine triple therapy
- Monitor: BP daily (hypertension), renal function daily, magnesium daily, cyclosporine trough, neurological exam (tremor, paresthesia, encephalopathy)
- Hold cyclosporine if creatinine rises >30% above baseline, magnesium <1.5, or new seizure
Sequential rescue: do not stack
Switching from one rescue therapy to another after failure (e.g., infliximab → cyclosporine or vice versa) is associated with high rates of serious infection (especially PJP and invasive fungal disease) and increased mortality. Patients failing first-line rescue should proceed to colectomy rather than receive sequential rescue. The exception may be carefully selected patients with strong contraindications to surgery, treated at experienced centers with intensive antimicrobial prophylaxis.
Day 5–7 reassessment
Reassess clinical response 5–7 days after initiating rescue therapy. Response is defined as a substantial reduction in stool frequency (typically <4–6 stools/day), absent or markedly reduced rectal bleeding, normalization of inflammatory markers (CRP), and improving albumin. Non-responders should proceed to surgery without delay.
6. Surgical Indications and Perioperative Care
Approximately 30% of ASUC patients require colectomy during the index admission. The standard emergency operation is subtotal colectomy with end ileostomy and Hartmann pouch (or mucous fistula), preserving the rectum for later proctectomy and IPAA (ileal pouch-anal anastomosis) consideration when the patient is clinically stable, off steroids, and well-nourished.
Emergency surgical indications
Immediate surgery (within 6–12 hours)
- Free perforation
- Massive lower GI hemorrhage requiring transfusion >6 units packed RBCs in 24 hours
- Toxic megacolon failing to respond to medical therapy within 24–72 hours
- Worsening sepsis despite broad-spectrum antibiotics and intensive care
- Acute deterioration with peritoneal signs
Urgent (semi-elective) surgical indications
Surgery within 24–72 hours
- Steroid failure (Oxford criteria positive at day 3) without medical rescue option
- Failure of medical rescue therapy at day 5–7
- Patient preference after informed discussion of rescue vs surgery risks
- High-grade dysplasia or carcinoma identified during admission
- Developing complications (severe corticosteroid adverse effects, opportunistic infection during rescue)
Operative approach
The standard operation for ASUC is subtotal colectomy with end ileostomy. Total proctocolectomy and IPAA is NOT performed during the index admission—the inflamed rectum, malnutrition, steroid effect on healing, and uncertain patient stability all increase pouch failure rates. Subtotal colectomy is performed via laparoscopic or open approach depending on surgeon preference, patient stability, and prior surgical history. Reconstruction (IPAA or Brooke ileostomy) is deferred to a second-stage operation 3–6 months later when the patient is in optimal condition.
Perioperative management
Perioperative orders
- Stress-dose hydrocortisone: Hydrocortisone 100 mg IV at induction, then 50 mg IV q6h × 24 hours, then taper
- Broad-spectrum antibiotics: Piperacillin-tazobactam 4.5 g IV q8h or Cefoxitin 2 g IV q6h for 24 hours post-op
- VTE prophylaxis: continue enoxaparin postoperatively; extended prophylaxis for 4 weeks post-discharge given high VTE risk
- Stoma care education and outpatient stoma nurse follow-up
- Ostomy supplies and home health referral arranged before discharge
- Counseling regarding planned second-stage surgery (timing, options: IPAA vs end ileostomy)
- Steroid taper: prednisone 40 mg PO daily, taper 5 mg/week post-discharge
7. Complications and Special Situations
Toxic megacolon
Toxic megacolon is defined as colonic dilation (transverse colon diameter >5.5 cm or cecum >9 cm on imaging) with at least three systemic features (fever ≥38°C, heart rate >120 bpm, leukocytosis >10,500/µL, or anemia) and at least one additional toxic feature (dehydration, altered mental status, electrolyte abnormality, hypotension). Mortality remains 10–20% with prompt management; perforation increases mortality to >50%.
Toxic megacolon management
- NPO and nasogastric decompression
- IV fluid resuscitation; correct electrolytes (especially potassium and magnesium)
- Broad-spectrum IV antibiotics: piperacillin-tazobactam 4.5 g IV q8h ± vancomycin 25 mg/kg IV load → AUC-guided maintenance if MRSA risk
- Continue IV steroids; do NOT abruptly stop
- Discontinue all antimotility, anticholinergic, and narcotic agents
- Reposition q2h (left-right rotation may aid colonic decompression)
- Imaging q6–12h: KUB to monitor colonic diameter; CT if change in clinical status
- Surgical consultation immediately; subtotal colectomy if no improvement in 24–72 hours, perforation, or hemodynamic deterioration
CMV reactivation
Colonic CMV reactivation occurs in 20–40% of steroid-refractory severe UC and is identified by tissue immunohistochemistry or PCR of biopsy specimens. Treatment is indicated when significant tissue burden is present (multiple inclusion bodies, high tissue PCR copies). The standard regimen is Ganciclovir 5 mg/kg IV q12h × 14–21 days with renal dose adjustment, followed by oral valganciclovir for completion if response. Continue UC therapy concurrently—antiviral treatment alone without addressing UC inflammation is inadequate.
C. difficile co-infection
C. difficile infection is identified in 5–25% of UC admissions and is associated with prolonged hospitalization and increased colectomy risk. Treatment is Vancomycin 125 mg PO QID × 14 days (oral, not IV—poor luminal penetration when IV). Severe or fulminant CDI may require Vancomycin 500 mg PO/PR QID + Metronidazole 500 mg IV q8h. Do NOT discontinue UC therapy during C. difficile treatment. Fidaxomicin 200 mg PO BID × 10 days is an alternative with lower recurrence rates.
Hemorrhage
Massive lower GI hemorrhage is rare in UC but life-threatening when it occurs. Initial management includes type and crossmatch, transfusion to maintain Hb >7–8 g/dL, correction of coagulopathy, and consultation with interventional radiology for possible angiographic embolization if a focal bleeding source is identified. Persistent hemorrhage requiring >6 units packed RBCs in 24 hours is an indication for emergency colectomy.
8. Discharge Criteria and Maintenance Plan
Discharge readiness
Discharge criteria (all must be met)
- Tolerating oral diet for ≥48 hours
- Stool frequency <6/day with minimal or no blood
- Resolved fever and tachycardia for ≥48 hours
- Tolerating oral steroid (prednisone 40 mg daily) without recrudescence
- Hemoglobin stable (no transfusion requirement for 48 hours)
- Normalized albumin trajectory (>3.0 g/dL or rising)
- Maintenance therapy plan in place (5-ASA optimization, biologic continuation, immunomodulator initiation)
- Outpatient follow-up scheduled within 1–2 weeks (gastroenterology) and 2 weeks (primary care)
- VTE prophylaxis continuation plan if extended prophylaxis indicated
- Patient education on warning signs (fever, abdominal pain, bloody stool >6/day, dehydration) with clear return precautions
Maintenance therapy planning
| Index admission therapy | Maintenance plan |
|---|---|
| Steroid-responsive ASUC, no prior maintenance | Optimize 5-ASA (mesalamine 4.8 g/day PO + 1 g enema/suppository) + initiate thiopurine (azathioprine 2–2.5 mg/kg/day) if recurrent flare |
| Steroid-responsive ASUC on existing 5-ASA | Initiate thiopurine OR transition to biologic (infliximab, adalimumab, vedolizumab, ustekinumab) |
| Infliximab rescue success | Continue infliximab 5 mg/kg q8 weeks; trough monitoring; consider adding thiopurine for combination therapy |
| Cyclosporine rescue success | Bridge to thiopurine or biologic within 3 months; cyclosporine cannot be sustained long-term |
| Surgical (subtotal colectomy) | Stoma care, nutrition optimization, plan second-stage surgery (IPAA vs Brooke ileostomy) at 3–6 months |
When to Escalate Care
Gastroenterology consultation: any UC admission, suspected IBD requiring confirmation, all rescue therapy candidates.
Colorectal surgery consultation: by hospital day 3 for all severe UC; immediately for toxic megacolon, perforation, hemorrhage.
Infectious diseases consultation: refractory C. difficile, opportunistic infection during immunosuppression, complex antibiotic decisions.
Stoma nurse consultation: pre-operative marking and post-operative education for all surgical candidates.
ICU transfer: hemodynamic instability, suspected perforation, massive hemorrhage, severe sepsis, toxic megacolon requiring intensive monitoring.
Clinical Pearls
- Day 3 is the inflection point—Oxford criteria identify steroid failures with 85% accuracy. Do not wait beyond day 5–7 to escalate.
- VTE prophylaxis is mandatory despite bloody diarrhea—UC inflammation is a strong prothrombotic state and bleeding does not contraindicate enoxaparin.
- Subtotal colectomy with end ileostomy is the standard emergency operation. IPAA is deferred to a planned second-stage procedure.
- Limited unprepped flexible sigmoidoscopy early in admission provides diagnostic clarity and CMV biopsy without the perforation risk of full colonoscopy.
- Surgery is not a failure—patients who undergo timely colectomy have better outcomes than those who experience prolonged steroid failure or sequential rescue therapy.
Common Pitfalls
- Continuing IV steroids beyond day 7 in a non-responder: each additional day of unmitigated severe disease increases postoperative mortality. Make a definitive decision by day 5.
- Sequential rescue therapy (IFX → CSA or vice versa): high rates of serious infection (especially PJP) and increased mortality. Failure of first-line rescue should prompt surgery.
- Empiric antibiotics for the UC flare itself: not indicated unless suspected toxic megacolon, perforation, sepsis, or proven coinfection. Routine antibiotics do not improve outcomes and select for resistant organisms.
- Withholding VTE prophylaxis due to rectal bleeding: this is the wrong instinct. Pharmacologic VTE prophylaxis does not increase clinically significant lower GI bleeding in active UC.
- Mistaking C. difficile or CMV as the sole cause: these are co-pathogens, not substitutes for UC therapy. Continue immunosuppressive treatment while addressing infection.
Frequently Asked Questions
9. Protocol Experience: Day-3 Reassessment Is the Most Important Decision Point
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)The stool chart at the end of the bed is filled in by whoever is passing and never totaled, and in a severe ulcerative colitis flare this disease is mismanaged most commonly at the day-3 decision point: patients who do not respond to IV corticosteroids by day 3-5 are too often continued on steroids alone, while the rescue medical therapy window (infliximab or cyclosporine) narrows and the trajectory toward colectomy steepens. The single most important order experienced practice adds to the admission set is "Day-3 stool frequency + CRP + clinical assessment with predefined rescue triggers."
The Truelove-Witts Criteria Experienced Practice Uses At Admission
Severe UC flare per Truelove-Witts requires: 6+ bloody bowel movements per day plus any of: fever >37.8°C, HR >90, hemoglobin <10.5, ESR >30 mm/h, or CRP >30 mg/L. In experienced hands, applying this at admission catches the patients who need IV steroids over PO and changes management. The Modified Mayo score adds endoscopic severity but is not always available at admission decision time. Experienced clinicians have stopped accepting "severe flare" as a clinical impression — experienced practice documents the Truelove-Witts criteria explicitly in the admission note to anchor management decisions.
Infection Exclusion Experienced Clinicians Do At Hour 0
Before any IV steroid, a clinical admission orders include: C. difficile NAAT + toxin, stool MCS culture, CMV serology + PCR plus consideration of biopsy for CMV inclusions if colonoscopy performed, ova and parasites in selected travel/exposure cases, and review of recent antibiotic exposure (recent CDI risk). Approximately 5-10% of "UC flares" are actually superimposed CDI or CMV — treating these as UC flare without identifying the infection produces worse outcomes. Experienced clinicians have a low threshold for sigmoidoscopy with biopsies looking for CMV inclusions, especially in steroid-refractory patients.
Day-3 Rescue Triggers Written as Standing Orders
the established standing order set includes day-3 reassessment with explicit rescue triggers: stool frequency >8/day OR CRP >45 mg/L OR no symptomatic improvement by day 3 on IV methylprednisolone 60 mg daily (or equivalent) → initiate medical rescue therapy (infliximab or cyclosporine) AND obtain surgical consultation. The Oxford and Stockholm criteria support this — patients meeting these criteria on day 3-5 have roughly 85% colectomy rate without rescue therapy. The clock starts at admission, not at day 7 when symptoms remain unchanged.
Infliximab vs Cyclosporine — Selection Logic
For medical rescue, infliximab 5 mg/kg IV is the preferred first choice because of established efficacy, simpler administration, and easier transition to maintenance therapy. Reserve cyclosporine 2 mg/kg/d IV for patients with contraindications to anti-TNF (active TB, severe heart failure, active infection), recent prior anti-TNF exposure with primary non-response, or patient preference. Seasoned clinicians check TPMT before starting either if azathioprine is planned for maintenance. Accelerated infliximab dosing (10 mg/kg) is considered in severe albumin loss (<3 g/dL) because of accelerated drug clearance — supported by emerging real-world evidence.
Illustrative Scenario — Steroid Continuation Past Day 5 Led to Emergency Colectomy
A man in his early thirties with known UC was admitted in severe flare (12 bloody BMs/day, fever 38.4°C, HR 108, Hgb 9.2, CRP 67). C. difficile was negative; CMV studies pending. Initial team started IV methylprednisolone 60 mg daily and ordered "reassess in 3 days." On day 3, he still had 9 BMs/day and CRP only modestly improved at 52 mg/L — meeting rescue trigger criteria. The covering team continued steroids alone "to see another 48 hours" without initiating rescue therapy. By day 6, abdominal distention developed with imaging showing megacolon (transverse colon 7.2 cm). The treating clinicians were consulted on day 6 — emergent colectomy was required. He survived but required permanent end-ileostomy and complications including parastomal hernia at 18 months. Earlier rescue therapy on day 3 might have avoided colectomy entirely.
Adjustments to Standard Severe UC Flare Order Set
- Truelove-Witts criteria documented at admission: 6+ bloody BMs/day plus any of fever, tachycardia, anemia, elevated ESR/CRP. Explicit documentation anchors the decision to IV (not PO) corticosteroids.
- Hour-0 infection exclusion before any steroid: CDI NAAT + toxin, stool MCS, CMV serology + PCR + biopsy if scoping. Low threshold for sigmoidoscopy with biopsies for CMV inclusions in steroid-refractory cases.
- Day-3 reassessment with explicit rescue triggers as standing orders: Stool >8/day OR CRP >45 OR no improvement → initiate rescue therapy AND surgical consultation in parallel. Do not extend steroid trial to day 5-7 without explicit reason.
- Infliximab 5 mg/kg first-line for rescue; accelerated dosing 10 mg/kg in albumin <3: Cyclosporine 2 mg/kg/d reserved for anti-TNF contraindications. Surgical consultation engaged in parallel — not after rescue therapy fails.
By hospital day 3–5 in any patient meeting Oxford criteria (>8 stools/day, OR 3–8 stools/day with CRP >45 mg/L). Each additional day of unmitigated severe disease increases the risk of complications and worsens outcomes if surgery is later required.
Both have comparable efficacy in head-to-head trials (CYSIF, CONSTRUCT) with similar 3-month colectomy rates. Choice is individualized: infliximab is preferred for patients planning long-term biologic maintenance, those with prior thiopurine exposure, or those with cyclosporine contraindications (cholesterol <120, hypomagnesemia, pregnancy). Cyclosporine is preferred for patients with prior anti-TNF failure, heart failure, or active untreated infection.
Active UC creates a strong prothrombotic state that increases VTE risk 3–6× compared to other medical admissions, with absolute risk of 1–4% for hospitalized patients. Multiple studies confirm that pharmacologic VTE prophylaxis (enoxaparin 40 mg SC daily) does not increase clinically significant lower GI bleeding in this population. Standard practice is to start within 24 hours of admission.
No. Routine empiric antibiotics do not improve outcomes in uncomplicated severe UC and may select for resistant organisms or precipitate C. difficile infection. Antibiotics are indicated only for documented coinfection (C. difficile, CMV, bacterial enteritis), suspected toxic megacolon, perforation, or sepsis.
Full colonoscopy with bowel prep is contraindicated in ASUC due to high perforation risk. Limited unprepped flexible sigmoidoscopy reaching only the descending colon (~30–40 cm) with minimal insufflation is preferred to confirm severity, exclude infection (especially CMV), and obtain biopsies. Full colonoscopy is deferred to outpatient follow-up after disease control.
Colectomy is preferred when: the patient has failed first-line rescue therapy, has contraindications to both infliximab and cyclosporine, develops complications (toxic megacolon, perforation, massive hemorrhage), has high-grade dysplasia or cancer, or chooses surgery after informed discussion of risks. Sequential rescue (switching from one therapy to the other after failure) is associated with high infection rates and mortality, making surgery the safer choice.
Subtotal colectomy with end ileostomy and Hartmann pouch (or mucous fistula) is the standard emergency operation, preserving the rectum for staged reconstruction. Total proctocolectomy with IPAA is NOT performed during the index admission due to high pouch failure rates in inflamed, malnourished, steroid-treated patients. Reconstruction (IPAA or Brooke ileostomy) is deferred 3–6 months until the patient is clinically stable, off steroids, and well-nourished.
- Severe Alcoholic Hepatitis Admission Order Set
- Severe Community-Acquired Pneumonia (CAP) Admission Order Set: ICU Triage, Antibiotics, Adjuncts, and Day-by-Day Workflow
- Alcohol Withdrawal Admission Order Set
- Hepatic Encephalopathy Admission Order Set: AASLD Lactulose Rifaximin Ammonia Workup and Precipitant Reversal
- STEMI Admission Order Set: Door-to-Balloon Pathway and Post-PCI Care
- Caustic Ingestion Admission Order Set: Initial Resuscitation, Endoscopy Timing, Zargar Grading, and Stricture Surveillance
Primary guideline documents this article draws on. Links resolve via DOI to the publisher; access may require a subscription.
- ACG 2019 Clinical Guideline: Ulcerative Colitis in Adults (American Journal of Gastroenterology · 2019)